We’re frequently asked in our comment section about: vitamin d and raynaud disease. Hopefully by the end of this article you’ll have no doubts about this subject.
Save Citation To File
Been studies to evaluate the effect of vitamin D supplementation on Raynaud’s phenomenon (RP). 42 patients were deficient in vitamin D dosage and randomly assigned into either the vitamin D group or placebo group. Every 4 weeks (for a total of 3 doses), patients received their treatment and answered on a visual analogue scale (VAS) basis about their RP.
42 patients were deficient in vitamin D dosage and randomly assigned into either the vitamin D group or placebo group. One can ask whether vitamin D has as a vasodilator effect in patients with RP who are deficient in vitamin D. Other studies and researches are needed to answer these question.
No Full-Text Available
The primary outcome variable was the number of new digital ulcers developing during the 16-week study period.
In patients receiving bosentan, a statistically significant improvement in hand function was observed. There was no difference between treatment groups in the healing of existing ulcers. Other side effects were similar in the 2 treatment groups.
Endothelins may play an important role in the pathogenesis of vascular disease in patients with SSc.
Vitamin D plays a well-known regulatory effect on both innate and adaptive immune systems (1). In humans, vitamin D is synthesized for the most part from cholesterol (7-dehydrocholesterol) in the skin under the effects of UV-B radiation and subsequently activated into 25OHD (calcidiol) in the liver and into 1,25(OH) 2 D (calcitriol) in the kidney.
For this reason, calcitriol is considered a steroid hormone (D hormone), sharing the cyclo-pentano-perhydro-phenanthrene ring structure of cholesterol with adrenal (cortisol) and gonadal (sexual) hormones (1). 25ohd deficiency is largely diffuse in general population and mainly in patients with a connective tissue disease (CTD) (2).